Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2662MR)

This product GTTS-WQ2662MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Non-small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2662MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9663MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ6738MR IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DS 992
GTTS-WQ6453MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CT-P23
GTTS-WQ1463MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ12711MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ6034MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ9547MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA J6M0
GTTS-WQ432MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 3C23K
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW